#abbvie

[ follow ]
#pharmaceuticals #dividend-investing #dividend-stocks #income-stocks #market-volatility #skyrizi #rinvoq
#dividend-stocks
Business
from24/7 Wall St.
2 days ago

10 Years, Zero Regrets: The Dividend Stocks I Keep Buying

Dividend stocks provide passive income and stability, with AbbVie being a strong choice due to its consistent dividend payments and growth potential.
more#dividend-stocks
from24/7 Wall St.
6 days ago

Price Prediction: Why AbbVie's Post-Humira Pivot Makes It a Strong Buy

AbbVie reported Q1 2026 revenue of $15 billion, beating the $14.72 billion consensus and growing 12.43% YoY. Adjusted EPS of $2.65 missed by $0.02, but a $744 million IPR&D charge clipped $0.41 per share.
Business
Business
from24/7 Wall St.
2 weeks ago

Why I Can't Stop Buying AbbVie Stock

AbbVie remains a strong investment due to its reliable dividends, successful product replacements, and undervalued growth potential.
#pfizer
Business
from24/7 Wall St.
2 weeks ago

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat - The Other Is Praying for a Pipeline Hit

AbbVie reported record net sales driven by Skyrizi and Rinvoq, while Pfizer faced revenue decline due to COVID-related impacts.
Business
from24/7 Wall St.
4 weeks ago

High Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower Payout

AbbVie shows strong growth with Skyrizi, while Pfizer struggles with declining COVID revenue and sustainability concerns in dividends.
Business
from24/7 Wall St.
2 weeks ago

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat - The Other Is Praying for a Pipeline Hit

AbbVie reported record net sales driven by Skyrizi and Rinvoq, while Pfizer faced revenue decline due to COVID-related impacts.
Business
from24/7 Wall St.
4 weeks ago

High Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower Payout

AbbVie shows strong growth with Skyrizi, while Pfizer struggles with declining COVID revenue and sustainability concerns in dividends.
more#pfizer
Business
from24/7 Wall St.
4 weeks ago

AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns

JPMorgan maintains an Overweight rating on AbbVie, viewing recent stock pullback as a buying opportunity with a $260 price target.
Healthcare
from24/7 Wall St.
4 months ago

This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence

Healthcare shows signs of stabilization and potential rebound driven by easing policy risks, clearer earnings, and increased M&A, with AbbVie as a dividend-led candidate.
#dividend-investing
more#dividend-investing
Medicine
from24/7 Wall St.
7 months ago

Top Dividend Stocks Poised for Explosive Growth in 2026 (ABBV, GD, RGR)

AbbVie shows strong stock performance near analyst targets, offers a 2.79% dividend yield, and markets a novel C‑MET–targeting oncology drug, Emrelis.
[ Load more ]